Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants
Open Access
- 1 July 2008
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 82 (13) , 6678-6688
Abstract
Human immunodeficiency virus type 1 (HIV-1) entry is an attractive target for therapeutic intervention. Two drugs that inhibit this process have been approved: the fusion inhibitor T20 (enfuvirtide [Fuzeon]) and, more recently, the CCR5 blocker maraviroc (Selzentry). T1249 is a second-generation fusion inhibitor with improved antiviral potency compared to the first-generation peptide T20. We selected T1249-resistant HIV-1 variants in vitro by serial virus passage in the presence of increasing T1249 doses after passage with wild-type and T20-resistant variants. Sequence analysis revealed the acquisition of substitutions within the HR1 region of the gp41 ectodomain. The virus acquired mutations of residue V38 to either E or R in 10 of 19 cultures. Both E and R at position 38 were confirmed to cause resistance to T1249, as well as cross-resistance to T20 and C34, but not to the third-generation fusion inhibitor T2635. We also observed substitutions at residues 79 and 90 (Q79E and K90E), which provide modest resistance to T1249 and, interestingly, T2635. Thus, the gp41 amino acid position implicated in T20 resistance (V38 replaced by A, G, or W) is also responsible for T1249 resistance (V38 replaced by E, R, or K). These results indicate that T20 and T1249 exhibit very similar inhibition modes that call for similar but not identical resistance mutations. All T1249-resistant viruses with changes at position 38 are cross resistant to T20, but not vice versa. Furthermore, substitutions at position 38 do not provide resistance to the third-generation inhibitor T2635, while substitution at positions 79 and 90 do, suggesting different resistance mechanisms.Keywords
This publication has 55 references indexed in Scilit:
- Mechanistic Studies of a T20-Dependent Human Immunodeficiency Virus Type 1 VariantJournal of Virology, 2008
- Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virusProceedings of the National Academy of Sciences, 2007
- Human Immunodeficiency Virus Type 1 Variants Resistant to First- and Second-Version Fusion Inhibitors and Cytopathic in Ex Vivo Human Lymphoid TissueJournal of Virology, 2007
- HIV-1 drug-resistance and drug-dependenceRetrovirology, 2007
- Evolutionary Repair of HIV Type 1 gp41 with a Kink in the N-Terminal Helix Leads to Restoration of the Six-Helix Bundle StructureAIDS Research and Human Retroviruses, 2004
- HIV-1 RNA Editing, Hypermutation, and Error-Prone Reverse TranscriptionScience, 2001
- Thermodynamics of trimer-of-hairpins formation by the SIV gp41 envelope proteinJournal of Molecular Biology, 2001
- Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane FusionJournal of Cell Biology, 2000
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994
- Determination of the helix and β form of proteins in aqueous solution by circular dichroismBiochemistry, 1974